VisEn Medical Inc.
This article was originally published in Start Up
VisEn Medical's core technology is based on activatable "smart imaging agents" and novel optical systems, including fluorescence-mediated tomography. The ability to visualize reactions and processes in vivo in real time using agents specifically activated by molecular targets, processes, or pathways-the molecular signatures of disease--may lead to breakthroughs that aren't possible with in vitro methods.
You may also be interested in...
Researchers at Memorial Sloan-Kettering and Cornell University have taken the first steps toward moving a silica-based nanoparticle platform invented at Cornell into use in cancer imaging. Using optical imaging and PET, they showed that encapsulating a dye in a biocompatible nanoscale matrix enhanced imaging capabilities while maintaining efficient clearance through the urine.
Biomolecular imaging is upgrading diagnostic imaging's stodgy reputation as scientists increasingly use it to improve both pharmaceutical research and clinical care. Part I of a two-part series explores researchers' excitement about biomolecular imaging's potential to improve the drug development process. Many companies see research applications as a way to prime the marketplace for clinical applications. But venture capitalists think research is a limited opportunity.
Tapping into the interplay between gut microbiota and an underappreciated subset of T cells could lead to therapies in a range of diseases.